Dr. David S. Boyer, MD

Dr. Boyer practices at Retina-Vitreous Associates Medical Group in Valley Village, California.

Dr. Boyer's NPI, 1295736916, was assigned on August 3, 2005. Dr. Boyer graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 1972. Dr. Boyer holds California license G25107.

Dr. Boyer's primary practice is Retina-Vitreous Associates Medical Group, at 12840 W Riverside Dr, Valley Village, CA 91607 in Los Angeles County. The practice phone is (213) 483-8810.

Dr. Boyer's primary practice is Retina-Vitreous Associates Medical Group in Valley Village, California. Dr. Boyer is also affiliated with PIH Health Good Samaritan Hospital. Dmand AI also links Dr. Boyer to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Boyer practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Boyer's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Boyer is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Boyer's licenses on file in 3 states: California, Hawaii and Pennsylvania.

Dmand AI lists age-related macular degeneration, cataract, dry eye, eyelid inflammation, glaucoma, hereditary corneal conditions, hypertensive retinopathy and inflammation of iris among the conditions Dr. Boyer treats.

CMS data shows 90,001 Medicare services from Dr. Boyer across 25 procedure codes in 2024, for 2,440 Medicare patients. Medicare paid $6,229,295 for them. Every service was in an office.

CMS counts 2,440 Medicare patients who saw Dr. Boyer in 2024. The largest group is 75 to 84, with 992 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Boyer's median patient age at 67, with 54% women.

In 2024, Dr. Boyer wrote 1,324 Medicare Part D claims for 344 patients. 64% of them were for generic drugs. CMS names the drug for 1,233 of them, across 26 drugs with 11 or more claims each, at $77,427 in total drug cost. In 2023, CMS named 1,343 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Boyer for performance year 2024, reported as part of a group. Dr. Boyer accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 177 papers to Dr. Boyer, published from 2009 to 2025. 2016 was the busiest year, with 12. The most frequent topics are Visual Acuity, Angiogenesis Inhibitors and Intravitreal Injections. Dr. Boyer has published most often in Ophthalmology. Dr. Boyer's most frequent co-authors are David M. Brown, MD, Diana V. Do, MD and Charles Clifton Wykoff, MD, PhD.

Dmand AI links Dr. Boyer to 18 clinical trials, 4 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Macular Degeneration, Diabetes Mellitus and Diabetic Retinopathy. Regeneron Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Boyer that name 3 trials.

CMS Open Payments shows 494 general payments to Dr. Boyer from 51 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 85% of the total. EyePoint Pharmaceuticals US, Inc. paid the most, $116,021. It also lists 14 research payments totaling $18,742 from 2016 to 2025, naming 3 clinical trials.

Dmand AI lists 5 awards for Dr. Boyer, most recently Top Doctors:LA Area in 2013.

Dr. Boyer graduated from Chicago Medical School at Rosalind Franklin University of Medicine and Science in 1972. Dr. Boyer is a member of AAO.

Dr. Boyer is in network with 17 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.